

Translated from [www.portaltucuma.com.br](http://www.portaltucuma.com.br) news article:

The study around the drug was conducted by the Same Group in partnership with the American dermatologist and researcher, Andy Goren, and the doctors Flávio Cadegiane (endocrinologist) and Ricardo Zimerman (infectologist).

In this occasion, the Secretary of Science and Technology of the Ministry of Health, Hélio Angotti Neto, participated in the live address alongside Bolsonaro.

It was reported that Proxalutamide is already in a state of approval by important agencies in the country such as Fiocruz, the Ministry of Health and the National Health Surveillance Agency (Anvisa), so that new studies are carried out nationwide through emergency use, and , from the approval, the medication is available throughout Brazil.

### **Study**

Hospitalized patients, who were over 18 years of age and had low oxygen saturation in room air — that is, they required oxygen (preferably in high flow), participated in the study.

These patients also had at least 25% to 50% of the affected lungs and the requirement was that they did not have major dysfunctions in the liver and kidneys.

In the placebo group — 294 patients — 141 deaths were recorded, equivalent to 47.6%. In the group that took Proxalutamide — 296...

Find more at [www.portaltucuma.com.br](http://www.portaltucuma.com.br)